Hayward, CA, May 22, 2018 – OptiScan Biomedical Corporation, a developer of an innovative continuous monitoring system for use in the surgical intensive care unit (SICU), today announced [...]
Pivotal study results published in the Journal of Trauma and Acute Care Surgery – June, 2017
OptiScan featured in front page article in Medical Device Daily – “Optiscan’s near continuous multianalyte monitoring device gains CE marking” – January 9, 2017
Peter Rule, Chairman and CEO, presented at the Canaccord Genuity Medical Technologies and Diagnostics Forum – November 2016
MANAGE IDE preliminary study results were presented at AAST in September 2016. Grant Bochicchio, primary investigator (Chief, Acute and Critical Care Surgery, Washington University School of Medicine, St Louis), said, “We are excited to have met both primary and secondary endpoints, but even more meaningful is the positive impact this innovation will have on clinical practice and patient outcomes.”
“MANAGE vs automated monitoring accuracy of Glucose II (MANAGE II)” – European study published in Critical Care – 2016 (20:380).
Results: MARD = 7.7%. Clarke Error Grid (CEG) was 99.9% in zones A and B.
OptiScan Biomedical Completes Enrollment of Pivotal U.S. Clinical Study of the OptiScanner 5000 System – November 2015
Regularly Attended Events:
Society of Critical Care Medicine (SCCM) – January
American Burn Association (ABA) – March
OptiScan Biomedical has received CE Mark certification for the OptiScanner 5000/6000 system.